Today San Francisco-based Medivation, Inc., ($MDVN) saw its stock value scale El Capitan within a day. This coming on the heels of Dendreon Corp. ($DNDN) losing a huge chunk of its stock value yesterday is a good example of human psychology. We reward "optimism" over "cautious behavior."
Showing posts with label astellas. Show all posts
Showing posts with label astellas. Show all posts
Thursday, November 3, 2011
Tuesday, February 1, 2011
Astellas Oncology: Dora's Estrellas in Astellas' Star-Pocket

Many of you may recall the spring of 2010 when Astellas tried to acquire OSI Pharmaceuticals - the barbs flew, as expected, until tons of Yens (to the tune of $4B) were offered to calm OSI and bring it into the Astelles family. That event signaled the maturing of Astellas as an oncology firm.
Labels:
agensys,
AGS-16M8F,
astellas,
erlotinib,
mdv3100,
prostate cancer,
renal cancer,
tarceva
Subscribe to:
Posts (Atom)